Dr Jonathan Goldman talks to ecancer at ASCO 2026 about findings from the phase III LIBRETTO-432 trial evaluating adjuvant selpercatinib in patients with early-stage RET fusion-positive lung cancer.

The study showed a reduction in recurrence risk following surgery or radiation, with Dr Goldman noting that it supports the growing role of targeted therapies in curative-intent lung cancer treatment and potentially changing clinical practice.

Read the news story here.